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Summary
Background In the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST), the composite 
primary endpoint of stroke, myocardial infarction, or death during the periprocedural period or ipsilateral stroke 
thereafter did not diﬀ er between carotid artery stenting and carotid endarterectomy for symptomatic or 
asymptomatic carotid stenosis. A secondary aim of this randomised trial was to compare the composite endpoint 
of restenosis or occlusion.
Methods Patients with stenosis of the carotid artery who were asymptomatic or had had a transient ischaemic attack, 
amaurosis fugax, or a minor stroke were eligible for CREST and were enrolled at 117 clinical centres in the USA and 
Canada between Dec 21, 2000, and July 18, 2008. In this secondary analysis, the main endpoint was a composite of 
restenosis or occlusion at 2 years. Restenosis and occlusion were assessed by duplex ultrasonography at 1, 6, 12, 24, 
and 48 months and were deﬁ ned as a reduction in diameter of the target artery of at least 70%, diagnosed by a peak 
systolic velocity of at least 3·0 m/s. Studies were done in CREST-certiﬁ ed laboratories and interpreted at the 
Ultrasound Core Laboratory (University of Washington). The frequency of restenosis was calculated by Kaplan-Meier 
survival estimates and was compared during a 2-year follow-up period. We used proportional hazards models to 
assess the association between baseline characteristics and risk of restenosis. Analyses were per protocol. CREST is 
registered with ClinicalTrials.gov, number NCT00004732.
Findings 2191 patients received their assigned treatment within 30 days of randomisation and had eligible 
ultrasonography (1086 who had carotid artery stenting, 1105 who had carotid endarterectomy). In 2 years, 58 patients 
who underwent carotid artery stenting (Kaplan-Meier rate 6·0%) and 62 who had carotid endarterectomy (6·3%) had 
restenosis or occlusion (hazard ratio [HR] 0·90, 95% CI 0·63–1·29; p=0·58). Female sex (1·79, 1·25–2·56), diabetes 
(2·31, 1·61–3·31), and dyslipidaemia (2·07, 1·01–4·26) were independent predictors of restenosis or occlusion after 
the two procedures. Smoking predicted an increased rate of restenosis after carotid endarterectomy (2·26, 1·34–3·77) 
but not after carotid artery stenting (0·77, 0·41–1·42).
Interpretation Restenosis and occlusion were infrequent and rates were similar up to 2 years after carotid endarterectomy 
and carotid artery stenting. Subsets of patients could beneﬁ t from early and frequent monitoring after revascularisation.
Funding National Institute of Neurological Disorders and Stroke and Abbott Vascular Solutions.
Introduction
In the Carotid Revascularization Endarterectomy versus 
Stenting Trial (CREST),1 no diﬀ erence was reported 
between carotid artery stenting and carotid endarter-
ectomy for the composite primary endpoint of stroke, 
myocardial infarction, or death during the periprocedural 
period or ipsilateral stroke thereafter. The secondary 
analysis of the individual components of the primary 
endpoint established that stroke occurred more fre-
quently after carotid artery stenting, as did myocardial 
infarction after carotid endarterectomy.1 That the 
frequency of the composite endpoint did not diﬀ er 
between carotid artery stenting and carotid endarter-
ectomy underscores the need for a comparison of the 
anatomic durability of these revascularisation proced-
ures. Many participants in CREST were asymptomatic, 
so the long-term durability of revascularisation becomes 
even more important.
The occurrence of restenosis after carotid artery 
stenting2–5 and carotid endarterectomy6–8 ranges from 5% 
to 20%, depending on its deﬁ nition and the duration of 
follow-up. Restenosis at 6 and 12 months were prespeciﬁ ed 
secondary endpoints in CREST. Before review of 
ultrasound data, the CREST investigators agreed that 
analysis at 24 months would be more informative and so 
decided that restenosis at 24 months would be the primary 
focus of this analysis. Hence, we report the 2-year 
anatomic durability of carotid artery stenting and carotid 
endarterectomy. We also identify factors aﬀ ecting risk of 
restenosis and compare frequency of stroke and repeat 
revascularisation between the treatment groups.
Methods
Study design and participants
The study design and the primary results of CREST have 
been reported previously.1,9,10 Brieﬂ y, patients were 
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enrolled at 117 clinical centres in the USA and Canada 
between Dec 21, 2000, and July 18, 2008. Patients who 
had had a transient ischaemic attack, amaurosis fugax, or 
a minor non-disabling stroke involving the study carotid 
artery within 180 days before randomisation were eligible 
if they had stenosis of 50% or more by angiography, 70% 
or more by ultrasonography, or 70% or more by computed 
tomo graphy angiography or magnetic resonance 
angiography when the stenosis by ultrasonography was 
50–69%. Patients who were asymptomatic were eligible 
when they had stenosis of 60% or more by angiography, 
70% or more by ultra sonography, or 80% or more by 
computed tomo graphy angiography or magnetic 
resonance angiography when the stenosis on ultra-
sonography was 50–69%. The full eligibility criteria have 
been reported elsewhere.1,9,10
The protocol was approved by the ethics committees of 
all study institutions and administrative sites. Written 
informed consent was obtained from all participants 
before their revascularisation procedure.
Randomisation and masking
Patients were randomly assigned to either carotid artery 
stenting or carotid endarterectomy through a web-based 
system with a permuted block design (random block 
sizes of two, four, or six), and were stratiﬁ ed according to 
centre and symptomatic status. Randomisation occurred 
after the patient and treating physician could arrange for 
revascularisation to be done within 2 weeks. Stroke and 
myo cardial infarction were adjudicated by specialty 
committees masked to treatment assignment. All other 
out comes were assessed by investigators unmasked to 
treat ment allocation. Investigators and patients were 
unmasked.
Procedures
Carotid endarterectomy was undertaken according to 
well established techniques (standard or eversion end-
arterectomy) on the basis of the individual preferences 
of 477 surgeons. Carotid artery stenting was undertaken 
with a prespeciﬁ ed self-expanding nitinol stent and an 
embolic protection device (RX Acculink and RX 
Accunet, Abbott Vascular, Santa Clara, CA, USA). 
224 participating interventionists were selected after 
successful comple tion of a mandatory non-randomised 
lead-in creden tialling phase of carotid artery stenting 
procedures.10,11 Full details of these procedures are 
provided elsewhere.1,9,10 
To maintain consistency in the follow-up timepoints, 
patients who underwent their assigned revascularisation 
procedure within 30 days of randomisation and who 
had at least one follow-up ultrasound within 24 months 
were included in this secondary analysis. Additionally, 
we focused on patients who received their assigned 
treatment, because we were interested in restenosis rates 
speciﬁ cally associated with carotid artery stenting and 
carotid endarterectomy (and not the intention to be 
treated by these procedures). Those who did not receive 
any treatment did not establish a condition of no stenosis 
that would have meant subsequent restenosis could 
occur.
Duplex ultrasonography was done at baseline and 1, 6, 
12, 24, and 48 months after revascularisation. Duplex 
ultrasonography12 was under taken at CREST-certiﬁ ed12 
clinical centre vascular la boratories with a standardised 
protocol that stipulated 16 doppler waveform samples at 
every examination (eight samples were taken from each 
side of the neck: six at 1–2 cm intervals along the common 
and internal carotid arteries, one from the external 
carotid artery, and one from the vertebral artery). 
Waveform samples were to be obtained at a 60-degree 
angle between the ultrasound beam and the long axis of 
the vessel. The highest systolic velocity measurement 
from each treated carotid pathway was used to identify 
restenosis.
Ultrasound laboratories use diﬀ erent methods and 
velocity measurements are angle-dependent.13 Accord-
ingly, ultrasound images and doppler waveforms were 
forwarded to the Ultrasound Core Laboratory at the 
University of Washington Ultrasound Reading Center 
(URC) for uniform assessment and coding. Clinical 
centres submitted ultrasound data primarily in digital 
form. A few centres submitted paper prints that were 
scanned and digitised at the URC. The velocity values 
submitted were entered into the URC database.
Images and waveforms were read by a registered 
sonographer certiﬁ ed by the American Registry of 
Diagnostic Medical Sonographers and trained by the 
URC. The reader conﬁ rmed images, values, and 
alignment of the ultrasound-beam cursor with the vessel 
axis on the B-mode image; image and waveform readings 
were then reviewed by a senior sonographer or the URC 
Director (KWB). Both reader and reviewer veriﬁ ed the 
selection, location, labelling of every image and waveform 
pair, and cursor alignment. When the cursor was 
misaligned, the doppler examination angle was measured 
again and the angle-adjusted velocity was recalculated. 
The equation for recalculation was: new velocity=old 
velocity × cos(old angle)/cos(new angle).
Corrections and changes marked in the reader and 
reviewer process were entered into the database and used 
to update the information. When the reviewer disagreed 
with the reader, the case was returned to the reader for 
conﬁ rmation. When the disagreement was not resolved, 
an adjudicator rendered a ﬁ nal decision and presented 
the case to the readers and reviewers to minimise future 
interpretation diﬀ erences. The ﬁ nal adjudicated angle-
adjusted velocity value and veriﬁ ed duplex ultra sono-
graphy was reported by the URC and these values were 
used in our analysis.
The main endpoint in this secondary analysis was 
a composite of restenosis, deﬁ ned as 70% or more 
diameter-reducing stenosis, or target-artery occlusion 
occurring at the ultrasound scans at 1, 6, 12, or 24 months. 
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The 70% threshold to deﬁ ne high-grade restenosis is the 
most accepted threshold and has been used in the Carotid 
and Vertebral Artery Transluminal Angioplasty Study 
(CAVATAS),3 the Stent-Protected Angioplasty versus 
Carotid Endarterectomy (SPACE) trial,4 and the 
Endarterectomy versus Angioplasty in Patients with 
Severe Symptomatic Carotid Stenosis (EVA-3S) trial.5 
Assessment of restenosis was done when the peak 
systolic velocity at any location within the treated internal 
or common carotid artery reached or exceeded 3·0 m/s. 
Analysis of the frequency of high-grade restenosis and 
occlusion was a prespeciﬁ ed secondary analysis of the 
CREST protocol. The decision to use 3·0 m/s as the 
deﬁ nition for restenosis was also made before un blinding 
of the restenosis data. Several single-institution reports14–18 
support the use of 3·0 m/s or more as an appropriate 
threshold to identify high-grade restenosis.
Target-artery occlusion was established on duplex 
ultrasonography when no ﬂ ow signal was detected at any 
location within the treated internal or common carotid 
artery. Included in this category were arteries with near 
occlusion deﬁ ned by a diastolic velocity of zero, low 
systolic velocity at some locations, or an inability to ﬁ nd 
doppler signals at some locations within the treated 
arterial segments. Residual stenosis immediately after 
re vascularisation was measured only in the group under-
going carotid artery stenting and was therefore not 
compared with carotid endarterectomy. The frequency 
with which ipsilateral stroke occurred in the period after 
procedures had been completed and the frequency of 
repeat surgical revascularisation, balloon angioplasty, or 
repeat carotid artery stenting done on target arteries were 
also assessed.
Concerns have been raised that ultrasound velocity 
criteria designed for native carotid arteries could over-
estimate stenosis in the presence of a stent,14,19 because 
the reduced compliance of the vessel wall could increase 
the peak systolic velocity.19 Therefore, use of an 
appropriate velocity threshold is central to the com-
parison of restenosis after carotid endarterectomy and 
carotid artery stenting. We have used the threshold of 
3·0 m/s to investigate the primary endpoint, acknow-
ledging that it is not universally accepted. To address 
potential threshold-dependent variations in restenosis 
determination, we undertook an exploratory analysis in 
which diﬀ erent thresholds (greater or less than 3·0 m/s) 
were applied to the data. Restenosis rates thus obtained 
for carotid artery stenting and carotid endarterectomy 
were compared.
Statistical analysis
The frequency of restenosis was calculated by Kaplan-
Meier survival estimates and was compared during a 
2-year follow-up period between patients undergoing 
carotid artery stenting and carotid endarterectomy. In 
analyses speciﬁ ed after the initial analysis plan but 
before the data were reviewed, we used proportional 
hazards analyses to assess the univariate association 
between baseline clinical charac teristics and the risk of 
the composite endpoint in the combined cohort and for 
carotid artery stenting and carotid endarterectomy 
separately to identify potential diﬀ erences in risk 
factors as deﬁ ned at the time of randomisation. 
Backwards stepwise procedures were used to establish 
the most parsimonious model for the combined cohort. 
We tested the clinical characteristics diabetes, 
dyslipidaemia, hypertension, smoking, pre vious 
cardiovascular disease or coronary artery bypass 
grafting, pretreatment stenosis category, age, symp-
tomatic status, ethnic origin, sex, time to treatment 
after randomisation, and antiplatelet treatment. The 
number of strokes that occurred in the 2 years after the 
procedures was compared by treatment group in the 
patients with and without the composite endpoint. 
Additionally, we compared the proportion of patients 
undergoing repeat revascularisation. Analyses were 
done with SAS (version 9.2).
CREST is registered with ClinicalTrials.gov, number 
NCT00004732.
Role of the funding source
Representatives of the study sponsors were involved in 
the review of the report and the study design, but were 
not directly involved in data collection, data management, 
data analysis, data interpretation, writing of the report, or 
the decision to submit for publication. The corres-
ponding author had full access to the data for this study 
and had ﬁ nal responsibility for the decision to submit for 
publication.
Results
Of the 1262 patients randomly assigned to carotid artery 
stenting who had data included in the main CREST 
analysis, 1136 received their allocated treatment and 
1123 did so within 30 days of randomisation. Of the 
1240 patients randomly assigned to carotid 
endarterectomy who had data included in the main 
CREST analysis, 1184 received their assigned treatment 
and 1151 did so within 30 days of randomisation. Reasons 
for patients not receiving their assigned treatment have 
been reported previously.1 Within our cohort, 37 patients 
who underwent carotid artery stenting and 46 who 
underwent carotid endarter ectomy did not have carotid 
duplex ultra sonography during follow-up data supplied 
to the Ultrasound Core Laboratory. Therefore, 
2191 patients received their as signed treatment within 
30 days of randomisation and had ultrasonography 
reviewed at the Ultrasound Core Laboratory, and form 
the analytic cohort for this report (1086 undergoing 
carotid artery stenting, 1105 under going carotid 
endarterectomy).
Table 1 shows baseline clinical characteristics. Patients 
excluded from this secondary analysis were older, less 
likely to be white or dyslipidaemic, and more likely to be 
Articles
758 www.thelancet.com/neurology   Vol 11   September 2012
female and have hypertension than were those who 
were included (table 1). Demographic charac teristics, 
symptomatic status, and risk-factor distribution did not 
diﬀ er between those who had carotid artery stenting 
versus those having carotid endarterectomy (table 1). 
However, patients who underwent carotid 
endarterectomy had their procedures slightly later than 
did those receiving carotid artery stenting, and more 
patients undergoing carotid artery stenting received 
antiplatelet treatment than did those assigned to carotid 
endarterectomy (table 1). The duration of follow-up of 
patients undergoing carotid artery stenting versus 
carotid endarterectomy was similar in our cohort (mean 
17·2 months [SD 7·9] vs 17·8 months [8·2]; median 
24 months [IQR 12–24] in both groups). The proportion 
of cases in which reanalysis of the images or discussion 
about the results occurred was small: reanalysis was 
necessary in 3·1% of patients at baseline, 2·9% at 
1 month, 2·2% at 6 months, 3·0% at 12 months, and 
1·6% at 24 months. 
The composite outcome of restenosis or occlusion 
occurred in 120 patients (58 carotid artery stenting, 
62 carotid endarterectomy). The Kaplan-Meier estimate 
for the frequency of the composite outcome in 2 years was 
6·0% for carotid artery stenting and 6·3% for carotid 
endarterectomy (hazard ratio [HR] 0·90, 95% CI 
Figure 1: Kaplan-Meier graph showing proportion of patients with restenosis or occlusion
More patients are included in this analysis than are listed in table 1 because some had ultrasonography at 36 or 
48 months but not at 24 months. Day 0 is the date of the relevant procedure.
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Carotid endarterectomy
Carotid artery stenting
CREST restenosis 
analysis cohort 
(n=2191)
CREST patients 
excluded from 
restenosis analysis 
(n=311)
p value Treatment groups
Carotid artery stenting 
group (n=1086)
Carotid endarterectomy 
group (n=1105)
p value
Age (years) 68·9 (8·8) 70·4 (9·0) 0·0041 68·6 (9·0) 69·1 (8·7) 0·2580
Women 742/2191 (34%) 130/311 (42%) 0·0060 382/1086 (35%) 360/1105 (33%) 0·1993
White 2057/2191 (94%) 275/311 (88%) 0·0003 1017/1086 (94%) 1040/1105 (94%) 0·6453
Symptomatic 1159/2191 (53%) 162/311 (52%) 0·7893 571/1086 (53%) 588/1105 (53%) 0·7661
Hypertension* 1868/2189 (85%) 273/303 (90%) 0·0255 919/1085 (85%) 949/1104 (86%) 0·4048
Diabetes† 667/2186 (31%) 92/303 (30%) 0·9578 325/1083 (30%) 342/1103 (31%) 0·6127
Dyslipidaemia‡ 1862/2181 (85%) 231/300 (77%) 0·0002 914/1081 (85%) 948/1100 (86%) 0·2813
Present smoker 573/2159 (27%) 73/301 (24%) 0·3982 291/1070 (27%) 282/1089 (26%) 0·4937
Previous cardiovascular disease or 
coronary artery bypass graft
965/2121 (46%) 119/290 (41%) 0·1519 471/1054 (45%) 494/1067 (46%) 0·4563
Pretreatment stenosis of at least 
70%
1884/2191 (86%) 267/310 (86%) 0·9466 938/1086 (86%) 946/1105 (86%) 0·6078
Systolic blood pressure (mm Hg) 141·4 (20·0); n=2177 142·0 (22·6); n=292 0·6402 141·4 (19·6); n=1078 141·3 (20·5); n=1099 0·8739
Diastolic blood pressure (mm Hg) 74·1 (11·5); n=2178 73·2 (11·5); n=291 0·2420 74·0 (11·6); n=1079 74·2 (11·4); n=1099 0·6815
Time from randomisation to 
treatment (days)
7 (3–11) ·· ·· 6 (2–10) 7 (3–12) 0·0184
Treatment within 7 days of 
randomisation
1249/2191 (57%) ·· ·· 645/1086 (59%) 604/1105 (55%) 0·0253
Lipid-lowering treatment§ 1664/1808 (92%) 197/220 (90%) 0·2046 824/889 (93%) 840/919 (91%) 0·3131
Antiplatelet treatment¶ 2038/2163 (94%) ·· ·· 1022/1059 (97%) 1016/1104 (92%) <0·0001
Antihypertensive treatment 1734/1805 (96%) 250/260 (96%) 0·9459 845/888 (95%) 889/917 (97%) 0·0506
Data are mean (SD), n/N (%), or median (IQR). Sample sizes vary for speciﬁ c characteristics because data are missing for a small number of patients. CREST=Carotid 
Revascularization Endarterectomy versus Stenting Trial. *Hypertension was deﬁ ned as a blood pressure of 140/80 mm Hg or more. †Diabetes was deﬁ ned by a fasting serum 
glucose concentration of 5 mmol/L or more or HbA1C of 42 mmol/L or more. ‡Dyslipidaemia was deﬁ ned by concentrations of low-density lipoproteins of 2·5 mmol/L or 
more. §Use of cholesterol medication was recorded only in those who answered aﬃ  rmatively to dyslipidaemia. ¶Additional details obtained since 2010 about antiplatelet 
treatment have been incorporated into this variable (addition of patients who received an appropriate loading dose of clopidogrel before carotid artery stenting), resulting in 
non-signiﬁ cant changes from percentages reported previously.1 
Table 1: Baseline clinical characteristics
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0·63–1·29; p=0·58, adjusted for age, sex, and symp-
tomatic status). 113 patients developed restenosis alone 
(56 carotid artery stenting, 57 carotid endarterectomy). In 
both groups, the Kaplan-Meier estimate of the 2-year 
frequency of restenosis was 5·8%. In the same period, 
eight patients developed an occlusion of the treated carotid 
artery, of which three (<1%) had had carotid artery stenting 
and ﬁ ve (<1%) carotid endarter ectomy. One patient who 
underwent carotid endarter ectomy had restenosis that 
subsequently occluded. Because of the fairly wide intervals 
between assessments during which restenosis could 
occur, we ﬁ tted a sensitivity analysis with a parametric 
accelerated failure time model to account for interval 
censoring and with underlying exponential and Weibull 
distributions. Neither provided evidence of a treatment 
diﬀ erence in restenosis rates (pexponential=0·35; pWeibull=0·34).
Although limited by the number of patients with 
duplex ultrasonography after 24 months (856 patients 
had an ultrasound at 36 months and 385 had one at 
48 months), our data can be used to provide initial long-
term estimated 48-month restenosis rates. The duration 
of follow-up of patients in this extended cohort was 
similar between groups (carotid artery stenting mean 
24·5 months [SD 14·7] vs carotid endarterectomy 
23·7 months [14·9]; median 24 months [IQR 12–36] in 
both groups). At 4 years, the composite outcome of 
restenosis or occlusion occurred in 122 patients 
(60 carotid artery stenting, 62 carotid endarterectomy). 
The Kaplan-Meier estimate for the frequency of the 
composite outcome in 4 years was 6·7% for carotid artery 
stenting and 6·2% for carotid endarterectomy (HR 0·94, 
95% CI 0·66–1·33; p=0·71, adjusted for age, sex, and 
symptomatic status; ﬁ gure 1).
Patients with the composite outcome were more likely 
to be younger, women, hypertensive, diabetic, and 
dyslipidaemic than were those who did not reach the 
outcome (table 2). Backwards stepwise analysis indicated 
female sex, diabetes, and dyslipidaemia were related to 
restenosis (table 2). Frequency of restenosis did not diﬀ er 
on the basis of symptomatic status (table 2). Frequency of 
restenosis in symptomatic versus asymptomatic patients 
was not signiﬁ cantly diﬀ erent in the carotid 
endarterectomy group (Kaplan-Meier estimate 6·0% 
[SE 1·1] vs 6·6% [1·1]; log rank p=0·42) or in those who 
underwent carotid artery stenting (4·9% [1·0] vs 7·2% 
[1·2]; log rank p=0·11).
Excluding 96 patients who had a periprocedural event, 
participants who had restenosis or occlusion within 
2 years were at greater risk for ipsilateral stroke after the 
periprocedural period up to the end of follow-up than 
were those who did not have restenosis (HR 4·37, 95% CI 
1·91–10·03; p=0·0005, adjusted for age, sex, and 
symptomatic status). Six of 56 patients who had undergone 
carotid endarterectomy and had restenosis and one of 55 
who had undergone carotid artery stenting had strokes 
after the periprocedural period. Of 1984 patients who did 
not have restenosis or a periprocedural event, ipsilateral 
strokes occurred in 30 (12 in the carotid endarterectomy 
group, 18 in the carotid artery stenting group).
Patients who developed restenosis were more likely to 
be women, hypertensive, diabetic, and dyslipidaemic than 
were those who did not develop restenosis, irrespective of 
No restenosis 
(n=2071)
Restenosis (n=120) p value for 
group 
diﬀ erences in 
composite 
endpoint 
Univariate HR 
(95% CI)
Multivariable 
HR (95% CI)*
Most 
parsimonious 
model HR 
(95% CI)
Carotid artery stenting 1028/2071 (50%) 58/120 (48%) 0·781 0·94 (0·65–1·34) 0·94 (0·65–1·37) ··
Age (years) 69·0 (8·8) 67·1 (9·6) 0·025 0·80 (0·66–0·98) 0·92 (0·73–1·17) ··
Women 686/2071 (33%) 56/120 (47%) 0·0023 1·75 (1·23–2·51) 1·83 (1·26–2·67) 1·79 (1·25–2·56)
White 1945/2071 (94%) 112/120 (93%) 0·7957 0·82 (0·40–1·68) 0·89 (0·43–1·86) ··
Symptomatic 1105/2071 (53%) 54/120 (45%) 0·0746 0·74 (0·51–1·05) 0·86 (0·58–1·28) ··
Hypertension† 1757/2069 (85%) 111/120 (93%) 0·0225 2·16 (1·09–4·25) 1·57 (0·78–3·14) ··
Diabetes‡ 607/2066 (29%) 60/120 (50%) <0·0001 2·39 (1·67–3·42) 2·22 (1·52–3·26) 2·31 (1·61–3·31)
Dyslipidaemia§ 1751/2062 (85%) 111/119 (93%) 0·0121 2·34 (1·14–4·80) 1·97 (0·90–4·31) 2·07 (1·01–4·26)
Present smoker 534/2041 (26%) 39/118 (33%) 0·0995 1·38 (0·94–2·03) 1·47 (0·95–2·27) ··
Previous cardiovascular disease or 
coronary artery bypass graft
909/2007 (45%) 56/114 (49%) 0·4242 1·18 (0·82–1·71) 1·07 (0·73–1·57) ··
Pretreatment stenosis of at least 70% 1779/2071 (86%) 105/120 (88%) 0·624 1·15 (0·67–1·97) 1·07 (0·6–1·93) ··
Treatment within 7 days of randomisation 1190/2071 (58%) 59/120 (49%) 0·0744 0·73 (0·51–1·04) 0·78 (0·53–1·15) ··
Antiplatelet treatment 1928/2046 (94%) 110/117 (94%) 0·9226 0·94 (0·44–2·01) 0·93 (0·43–2·01) ··
Data are n/N (%) or mean (SD), unless otherwise stated. The combined restenosis cohort includes patients who underwent carotid artery stenting or carotid endarterectomy. 
The most parsimonious model indicates risk factors that were most likely to be associated with restenosis after revascularisation. Sample sizes vary for speciﬁ c characteristics 
because data are missing for a small number of patients. HR=hazard ratio. *Adjusted for all variables. †Hypertension was deﬁ ned as a blood pressure of 140/80 mm Hg or 
more. ‡Diabetes was deﬁ ned by a fasting serum glucose concentration of 5 mmol/L or more or HbA1C of 42 mmol/L or more. §Dyslipidaemia was deﬁ ned by concentrations of 
low-density lipoproteins of 2·5 mmol/L or more. 
Table 2: Comparison of clinical characteristics of patients with or without restenosis
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treatment, on univariate analysis (table 3). However, 
smoking was associated with restenosis after carotid 
endarterectomy, but not after carotid artery stenting 
(table 3). Restenosis was more common in smokers than 
in non-smokers who underwent carotid endarterectomy 
(Kaplan-Meier estimate 10·6% [SD 2·0] vs 4·7% [0·8], log 
rank p=0·0012), but no diﬀ erence was recorded in those 
who underwent carotid artery stenting (5·5% [1·5] vs 
6·3% [0·9], log rank p=0·39). 43 patients had repeat 
revascularisation in 2 years of follow-up. Of those, 20 had 
previously undergone carotid artery stenting and 23 had 
undergone carotid endarterectomy (p=0·69). 15 patients 
underwent repeat revascularisation without conﬁ rmation 
of the presence of a restenosis by our criteria.
In the exploratory analysis, diﬀ erent thresholds of peak 
systolic volume yielded variable frequencies of the 
composite endpoint (ﬁ gure 2). However, the frequencies 
diﬀ ered by treatment received only for the 2·1 m/s 
threshold (log rank p=0·02; ﬁ gure 2).
Discussion
Our results provide three key ﬁ ndings. First, carotid 
artery stenting and carotid endarterectomy are 
associated with similar frequencies of restenosis in 
patients with symptomatic or asymptomatic carotid 
stenosis. Second, female sex, diabetes, and 
dyslipidaemia are independent predictors of restenosis 
after carotid artery stenting and carotid endarterectomy, 
but smoking was associated with an increased 
likelihood of restenosis after carotid endarterectomy. 
Finally, restenosis is associated with an increased risk 
of ipsilateral stroke after both procedures.
We have analysed 2-year follow-up data for 
2191 conventional-risk patients, of whom almost half 
were asymptomatic. Our study is the most com-
prehensive investigation of restenosis after carotid 
revascularisation (panel). Patients were given available 
pharmacological, surgical, and endovascular treatments. 
The results are therefore readily applicable to clinical 
Panel: Research in context
Systematic review
We searched PubMed for reports published in English between 
Jan 1, 1990, and April 30, 2012, with the terms “clinical trials”, 
“carotid endarterectomy”, “carotid stenting”, “restenosis”, and 
“recurrent stenosis”. References within these reports were also 
checked for additional related citations. We manually reviewed 
the reports and identiﬁ ed those of multicentre randomised 
trials with available information about enrolment and 
outcomes during follow-up. We identiﬁ ed four trials of 
restenosis in patients who had undergone carotid artery 
stenting or carotid endarterectomy.3–5,20 We noted that published 
trials have varying conclusions (table 4): they have shown no 
diﬀ erence in restenosis, an increase in frequency after 
endarterectomy, or an increase in frequency after stenting. 
However, bare-metal stenting in the coronary artery is known to 
be associated with increased rates of recurrent stenosis.21
Interpretation
On the basis of the results from the previous trials,3–5,20 we did 
this secondary analysis of CREST with the hypothesis that 
carotid artery stenting would result in a higher rate of 
restenosis than would carotid endarterectomy. The large 
number of patients included in our study—many of whom 
were asymptomatic—means that it is the most comprehensive 
analysis of restenosis after carotid revascularisation. We have 
shown that the procedures are associated with similar rates of 
restenosis. Our results provide reassurance that carotid 
revascularisation is durable, and identify subsets of patients 
that might beneﬁ t from close surveillance for recurrence.
Figure 2: Frequency of restenosis after carotid artery stenting or endarterectomy with diﬀ erent PSV 
thresholds
Bars indicate SE. PSV=peak systolic velocity.
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Carotid artery 
stenting univariate 
HR (95% CI)
Carotid 
endarterectomy 
univariate HR (95% CI)
Interaction 
p value*
Age (per diﬀ erence of 10 years) 0·90 (0·68–1·20) 0·72 (0·54–0·95) 0·2612
Women 1·42 (0·84–2·39) 2·15 (1·30–3·53) 0·2606
White 0·66 (0·26–1·65) 1·09 (0·34–3·46) 0·5076
Symptomatic 0·66 (0·39–1·11) 0·82 (0·50–1·34) 0·5506
Hypertension 3·37 (1·05–10·76) 1·55 (0·67–3·60) 0·2896
Diabetes 2·44 (1·46–4·08) 2·35 (1·43–3·86) 0·9167
Dyslipidaemia 5·12 (1·25–20·96) 1·42 (0·61–3·30) 0·1265
Present smoker 0·77 (0·41–1·42) 2·26 (1·34–3·77) 0·0081
Previous cardiovascular disease or coronary 
artery bypass graft
1·28 (0·75–2·19) 1·10 (0·66–1·82) 0·6789
Pretreatment stenosis of at least 70% 1·68 (0·67–4·19) 0·89 (0·45–1·74) 0·2725
Treatment within 7 days of randomisation 0·79 (0·47–1·33) 0·67 (0·41–1·10) 0·6475
Antiplatelet treatment 1·94 (0·27–14·04) 0·78 (0·34–1·81) 0·4059
The interaction analysis indicates a risk factor or risk factors that were associated with restenosis after one but not the 
other revascularisation procedure. *p values refer to the presence or absence of a signiﬁ cant interaction between type 
of revascularisation procedure and risk factor for the outcome of restenosis.
Table 3: Clinical characteristics as potential predictors of restenosis according to revascularisation procedure
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practice. Randomised trials of medical management 
versus carotid endarterectomy have not included an 
assessment of restenosis.22–24 Other trials of carotid artery 
stenting versus carotid endarterectomy3–5,20 have analysed 
restenosis rates (table 4), but with smaller numbers of 
patients than in our analysis. The Stenting and 
Angioplasty with Protection in Patients at High Risk for 
Endarterectomy (SAPPHIRE) trial20 included 
260 symptomatic patients deemed at high risk of poor 
outcome after surgery. CAVATAS3 had 413 conventional-
risk patients, of whom 95% were symptomatic; of the 
200 patients in its endovascular group, only 50 received a 
carotid artery stent. The SPACE trial (n=1063)4 and the 
EVA-3S trial (n=507)5 also included only symptomatic 
patients (table 4).
Carotid artery revascularisation is a durable 
procedure. 2-year frequencies of our composite 
endpoint after carotid artery stenting and carotid 
endarterectomy provide a guide with which to compare 
future studies. Although our initial estimates to 4 years 
showed similar frequencies to those for 2 years, we 
prefer to focus on the 2-year values because the number 
of patients who had been followed to 48 months was 
small and so these estimates could be inaccurate. Initial 
concerns had been expressed regarding exaggerated 
neointimal hyperplasia after carotid artery stenting on 
the basis of experience with coronary21 and intracranial 
arterial25 bare-metal stenting. These concerns were not 
substantiated in CREST. Low restenosis rates after 
carotid stenting have also been reported in small single-
institution studies and ran domised trials (table 4).
We noted no diﬀ erence in 2-year frequency of 
restenosis between the groups after adjusting for age, 
sex, and symptomatic status. However, the SPACE trial4 
showed that restenosis occurred more frequently in 
2 years after carotid artery stenting than after carotid 
endarterectomy (11·1% vs 4·6% of patients; p=0·0007). 
The CREST results oﬀ er the highest reliability and 
uniformity of comparison, because ultrasonography was 
read centrally with uniform and updated velocity criteria 
for the endpoint.12 In SAPPHIRE,20 re intervention was 
used as a surrogate for restenosis, with the assumption 
that the reinterventions were all done at the assigned 
threshold of a diameter reduction of 80% or more. In 
SPACE,4 restenosis interpretations reported from 
individual clinical centres were used. In EVA-3S,5 most 
ultrasound tests were done outside the participating 
centres, and an unspeciﬁ ed number of outcomes were 
based on written reports from clinical centres. Frequency 
of restenosis after 2 years remains unknown because 
previous studies have shown that restenosis can be 
reported 2 years after carotid artery stenting or carotid 
endarterectomy. Accordingly, the CREST cohort is being 
followed up to 10 years with annual ultrasonography.
The deﬁ nition of restenosis in CREST was based on 
the criteria used in previously published trials.4,5,20 
Although restenosis has sometimes been deﬁ ned as 
any diameter reduction of at least 50%, the clinical 
relevance of this deﬁ nition is not established, and we 
did not seek to identify this subset of patients. Duplex 
ultrasound velocity thresholds to derive estimates of 
stenosis in native carotid arteries are well established 
and validated.26,27 The CREST deﬁ nition of 3 m/s or 
more was based on a comparison of more than 
500 duplex ultrasound and anatomical comparative 
imaging studies. The SPACE investigators used a lower 
peak systolic velocity threshold4—2·1 m/s—which 
could explain why the frequency of restenosis was 
higher than in EVA-3S,5 in which a threshold of 3·0 m/s 
was used. As the threshold was reduced in our 
exploratory analysis, the frequency of restenosis 
increased more in patients who had undergone carotid 
Recruitment period Deﬁ nition of restenosis Diagnostic criteria Number of patients Patients with restenosis
Start End Carotid 
artery 
stenting
Carotid 
endarterectomy
Carotid artery 
stenting
Carotid 
endarterectomy
p value
CAVATAS3 March, 1992 July, 1997 Restenosis ≥70% or 
occlusion
PSV >2·1 m/s 50 213 16·6% in 5 years 10·5% in 5 years Not 
reported
SAPPHIRE20 August, 2000 July, 2002 Restenosis ≥50% 
(symptomatic) and 
≥80% (asymptomatic)
Repeat revascularisation 
procedure
143 117 3% in 3 years 7·1% in 3 years 0·08
EVA-3S5 November, 2000 September, 2005 Restenosis ≥70% or 
occlusion
PSV ≥2·1 m/s (carotid 
endarterectomy) and ≥3·0 m/s 
(carotid artery stenting)
242 265 3·3% in 3 years 2·8% in 3 years Not 
signiﬁ cant
CREST1 December, 2000 July, 2008 Restenosis ≥70% or 
occlusion
PSV ≥3·0 m/s 1086 1105 6·0% in 2 years 6·3% in 2 years 0·58
SPACE4 March, 2001 February, 2006 Restenosis ≥70% or 
occlusion
Not speciﬁ ed 541 522 11·1% in 2 years 4·6% in 2 years 0·0007
CAVATAS=Carotid and Vertebral Artery Transluminal Angioplasty Study. PSV=peak systolic velocity. SAPPHIRE=Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy. 
EVA-3S=Endarterectomy versus Angioplasty in Patients with Severe Symptomatic Carotid Stenosis. CREST=Carotid Revascularization Endarterectomy versus Stenting Trial. SPACE=Stent-protected Angioplasty 
versus Carotid Endarterectomy.
Table 4: Frequency of restenosis after carotid artery stenting or carotid endarterectomy in trials from Europe, Canada, and the USA
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artery stenting than in those who had had carotid 
endarterectomy. However, we noted a signiﬁ cant 
diﬀ erence only with the 2·1 m/s threshold.
Previous trials have identiﬁ ed risk factors for 
restenosis on the basis of assessments of patients after 
carotid artery stenting and carotid endarterectomy as a 
combined group. In CREST, patients with restenosis 
were most likely to be women with diabetes and 
dyslipidaemia. No previous randomised trial has 
identiﬁ ed an increased likelihood for women to develop 
restenosis after carotid revascularisation. Previous 
single-institution studies of carotid artery stenting28 and 
larger studies of coronary and intracranial arteries25 
have implied that diabetes is a risk factor for recurrent 
stenosis after carotid stenting. This association has not 
been identiﬁ ed in other trials of carotid artery stenting 
or carotid endarterectomy. The SAPPHIRE20 and 
SPACE4 trials did not include assessments of risk 
factors. Smoking in the CAVATAS trial3 and increasing 
age in EVA-3S5 were shown to predict restenosis.
The injury patterns and biological eﬀ ects of the two 
procedures are probably diﬀ erent. They could be aﬀ ected 
diﬀ erently by clinical characteristics of patients. We 
showed that the risk factors for restenosis were generally 
similar for carotid artery stenting and for carotid 
endarterectomy, but that smoking diﬀ ered with pro-
cedure. A variable eﬀ ect of risk factors on restenosis after 
carotid artery stenting compared with carotid 
endarterectomy has not been identiﬁ ed previously.
Our results indicate that restenosis was associated 
with an increased risk of ipsilateral stroke after carotid 
artery stenting or carotid endarterectomy. Occurrence 
of both stroke and restenosis was identiﬁ ed at the time 
of an assigned follow-up. Therefore, we cannot state 
with certainty whether restenosis developed before or 
after stroke. Furthermore, restenosis is cumulative and 
results from progressive accumulation of neointimal or 
atherosclerotic material. On the basis of our protocol, 
we can clearly deﬁ ne the time of diagnosis of restenosis 
and not the time of development of restenosis. A 
limitation of the study is that the results do not allow 
inference about the potential need for repeat carotid 
artery stenting or carotid endarterectomy to address the 
increased risk of stroke. Repeat revascularisation for 
restenosis was infrequent. Because the threshold 
restenosis at which these procedures were undertaken 
was not protocol-driven in CREST, some patients 
received reintervention without an established 
diagnosis of high-grade stenosis from the Ultrasound 
Core Laboratory. The method of revascularisation was 
not protocol-driven and ranged from repeat 
endarterectomy to balloon angioplasty or repeat 
stenting.
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